Stay invested in GSK Pharma: Harendra Kumar

Harendra Kumar of Elara Capital told CNBC-TV18, "For long-term shareholders, it is best that they invested and not surrender GlaxoSmithKline Pharmaceuticals. It is a very steady growth rate company with around 10-15 percent year-on-year (Y-o-Y). Progressively, India will become important market for introduction of new drug. I understand they are also working on launches of some very blockbuster vaccines."

"For long-term investors, it would be meaningful to stay invested and not surrender the shares," he added.